SCHEDULE 13G: Alumni Capital LP Discloses 9.99% Stake in Kazia Therapeutics, Holds Warrants for Larger Potential Ownership

Alumni Capital LP, along with its general partner and manager, has disclosed a 9.99% beneficial ownership stake in Kazia Therapeutics Limited, while also holding warrants that could significantly increase their ownership if certain exercise limitations were removed.

Summary

• Alumni Capital LP, Alumni Capital GP LLC, and Ashkan Mapar (manager of Alumni Capital GP LLC) have jointly filed a Schedule 13G, disclosing beneficial ownership in Kazia Therapeutics Limited.
• As of January 10, 2025, the reporting persons collectively beneficially own 558,918 American Depositary Shares (ADSs) of Kazia Therapeutics Limited.
• This ownership represents 9.99% of the outstanding class of American Depositary Shares.
• The reported beneficial ownership includes 553,440 ADSs directly held by Alumni Capital LP and 5,478 ADSs underlying presently exercisable pre-funded warrants.
• The filing explicitly states that it excludes 774,415 ADSs underlying pre-funded warrants and 1,598,715 ADSs underlying warrants due to a self-imposed 9.99% 'Exercise Blocker'.
• Without this 9.99% Exercise Blocker, Alumni Capital LP would be deemed to beneficially own a total of 1,598,715 ADSs.
• The beneficial ownership calculation is based on 5,589,294 ADSs outstanding plus 5,478 ADSs issuable upon exercise of presently exercisable pre-funded warrants.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a strong positive or negative sentiment. The existence of warrants and an exercise blocker are neutral facts.

Positives

• A significant beneficial ownership stake by an institutional investor like Alumni Capital LP may signal confidence in Kazia Therapeutics Limited's long-term prospects.
• The investor's substantial potential ownership, if the self-imposed blocker were removed, indicates a deeper interest and potential for increased future investment or influence.

Negatives

• The self-imposed 9.99% 'Exercise Blocker' limits Alumni Capital LP's immediate ability to convert all their warrants into ADSs, potentially capping their direct influence or stake at the current time.

Risks

• The existence of a significant number of unexercised warrants (774,415 pre-funded warrants and 1,598,715 warrants) held by Alumni Capital LP, which are currently subject to an 'Exercise Blocker', represents potential future dilution if these blockers are removed and the warrants are exercised.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant ownership stake by an institutional investor in a publicly traded company. It does not provide information on broader industry trends or competitive landscape, but rather focuses on a specific company's ownership structure.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a near-10% stake, with potential for a much larger stake, could influence investor perception and potentially the stock's trading dynamics.

Key Dates

Keywords

Kazia Therapeutics Limited, Alumni Capital LP, Schedule 13G, Beneficial Ownership, American Depositary Shares, ADS, Warrants, Pre-funded Warrants, Exercise Blocker, Institutional Investor, SEC Filing